M2SR
Influenza Prevention (Supra-seasonal)
Key Facts
About FluGen
FluGen is a private, pre-revenue biotech founded in 2007 and based in Madison, Wisconsin, focused on revolutionizing influenza vaccination. Its lead candidate, M2SR, is an intranasal, live-attenuated vaccine platform in clinical development, designed to provide broader and more durable protection than annual shots by targeting the site of infection and inducing a multi-faceted immune response. The company has raised over $40 million, completed multiple human trials, and is exploring the platform's application against other respiratory diseases like COVID-19 and RSV. FluGen's strategy targets the significant $5 billion annual flu vaccine market, where efficacy, especially in vulnerable populations, remains a major challenge.
View full company profile